Levy Y, Gahery-Segard H, Durier C, Lascaux A.S., Goujard C, Meiffrédy V, Rouzioux C, Habib R, Beumont-Mauviel M, Guillet JG, Delfraissy JF, Aboulker JP, and the ANRS 093 Study Group. Immunological and virological efficacy of a therapeutic immunization
combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005, 19:279-86. Lien PubMed
Morand-Joubert
L, Marcellin F, Launay O, Guiramand-Hugon S, Gerard L, Yeni P, Aboulker
JP, for the Agence Nationale de Recherches sur le SIDA 081 Study Group.Contribution
of cellular HIV-1 DNA quantification to the efficacy analysis of
antiretroviral therapy: a randomised comparison of 2 regimens, including
3 drugs from 2 or 3 classes. J Acquir Immune Defic Syndr 2005, 38:268-76. Lien PubMed
Descamps D, Joly V, Flandre P, Peytavin G, Meiffrédy V, Delarue S, Lastère S, Aboulker JP, Yeni P, Brun-Vézinet F.Genotypic
resistance analyses in nucleoside-pretreated patients failing an
indinavir containing regimen: results from a randomized comparative
trial : (Novavir ANRS 073). J Clin Virol 2005, 33:99-103. Lien PubMed
Verstuyft
C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentré F,
Peytavin G, Gérard L, Becquemont L, Aboulker JP, for the ANRS 081 Study
Group. Absence of association between MDR1 genetic
polymorphisms, indinavir pharmacokinetics and response to highly active
antiretroviral therapy. AIDS 2005, 19 :2127-31. Lien PubMed
Hoen
B, Fournier I, Lacabaratz C, Burgard M, Charreau I, Chaix ML, Molina
JM, Livrozet JM, Venet A, Raffi F, Aboulker JP, Rouzioux C for the
Primstop study group.Structured Treatment Interruptions in Primary HIV-1 Infection: the ANRS 100 PRIMSTOP Trial J AIDS 2005, 40:307-16.Lien PubMed
Dunn
DT, Gibb DM, Duong T, Babiker AG, Aboulker JP, Bulterys M,
Cortina-Borja M, Gabiano C, Galli L, Giaquinto C, Harris DR, Hughes M,
McKinney R, Moye J, Newell ML, Pahwa S, Palumbo P, Rudin C, Sharland M,
Shearer W, Thompson B, Tookey P.Use of total lymphocyte count
for informing when to start antiretroviral therapy in HIV-infected
children: a meta-analysis of longitudinal data. Lancet 2005, 366:1868-74.Lien PubMed
Payen S, Faye A, Compagnucci A, Giaquinto C, Gibbs D, Gomeni R, Bressolle F, Jacqz-Aigrain E.Bayesian
parameter estimates of nelfinavir and its active metabolite,
hydroxy-tert-butylamide, in infants perinatally infected with human
immunodeficiency virus type 1. Antimicr Ag Chem 2005, 49:525-35.Lien PubMed